Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.334
Abstract: e16059Background: Trastuzumab combined with chemotherapy is the standard first-line regimen in HER2- overexpression advanced gastric cancer, and there is no established therapy in the second-line s... read more here.
Keywords: pharmacokinetics efficacy; overexpression advanced; safety pharmacokinetics; her2 overexpression ... See more keywords